588 related articles for article (PubMed ID: 32729235)
1. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
2. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
3. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS.
Carey RM; Brody RM; Shimunov D; Shinn JR; Mady LJ; Rajasekaran K; Cannady SB; Lin A; Lukens JN; Bauml JM; Cohen RB; Basu D; O'Malley BW; Weinstein GS; Newman JG
Laryngoscope; 2021 Dec; 131(12):E2865-E2873. PubMed ID: 34076275
[TBL] [Abstract][Full Text] [Related]
4. Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma.
Rasmussen JH; Grønhøj C; Håkansson K; Friborg J; Andersen E; Lelkaitis G; Klussmann JP; Wittekindt C; Wagner S; Vogelius IR; von Buchwald C
Ann Oncol; 2019 Apr; 30(4):629-636. PubMed ID: 30657857
[TBL] [Abstract][Full Text] [Related]
5. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
6. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy.
Carpén T; Saarilahti K; Haglund C; Markkola A; Tarkkanen J; Hagström J; Mattila P; Mäkitie A
Strahlenther Onkol; 2018 Aug; 194(8):759-770. PubMed ID: 29774396
[TBL] [Abstract][Full Text] [Related]
7. Oropharyngeal Squamous Cell Carcinoma With Discordant p16 and HPV mRNA Results: Incidence and Characterization in a Large, Contemporary United States Cohort.
Shinn JR; Davis SJ; Lang-Kuhs KA; Rohde S; Wang X; Liu P; Dupont WD; Plummer D; Thorstad WL; Chernock RD; Mehrad M; Lewis JS
Am J Surg Pathol; 2021 Jul; 45(7):951-961. PubMed ID: 33739785
[TBL] [Abstract][Full Text] [Related]
8. Nodal response after 46 Gy of intensity-modulated radiotherapy is associated with human papillomavirus-related oropharyngeal carcinoma.
Dronkers EAC; Koljenovic S; Verduijn GM; Baatenburg de Jong RJ; Hardillo JAU
Laryngoscope; 2018 Oct; 128(10):2333-2340. PubMed ID: 29521420
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of p16
Wagner S; Prigge ES; Wuerdemann N; Reder H; Bushnak A; Sharma SJ; Obermueller T; von Knebel Doeberitz M; Dreyer T; Gattenlöhner S; Wolf G; Pons-Kühnemann J; Wittekindt C; Klussmann JP
Br J Cancer; 2020 Sep; 123(7):1114-1122. PubMed ID: 32624580
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
[TBL] [Abstract][Full Text] [Related]
11. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma.
Oguejiofor KK; Hall JS; Mani N; Douglas C; Slevin NJ; Homer J; Hall G; West CM
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):630-8. PubMed ID: 23916365
[TBL] [Abstract][Full Text] [Related]
13. Radiation Therapy Alone for Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study.
Takemoto N; Seo Y; Nakahara S; Yoshioka Y; Teshima T; Fujii T; Isohashi F; Otani K; Yoshii T; Takenaka Y; Suzuki M; Fukusumi T; Hanamoto A; Yasui T; Michiba T; Yamamoto Y; Shimamoto S; Tanaka H; Tatsumi M; Ogawa K; Inohara H
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):403-411. PubMed ID: 33373656
[TBL] [Abstract][Full Text] [Related]
14. Discrepancy in p16 expression in patients with HPV-associated head and neck squamous cell carcinoma in Thailand: clinical characteristics and survival outcomes.
Arsa L; Siripoon T; Trachu N; Foyhirun S; Pangpunyakulchai D; Sanpapant S; Jinawath N; Pattaranutaporn P; Jinawath A; Ngamphaiboon N
BMC Cancer; 2021 May; 21(1):504. PubMed ID: 33957888
[TBL] [Abstract][Full Text] [Related]
15. Concurrent HPV-related oropharyngeal carcinoma in four couples.
Sathasivam HP; Bhatia R; Bradley P; Robson A; Paleri V; Cocks H; Oozeer N; Milne D; Sloan P; Robinson M
Oral Oncol; 2018 Nov; 86():33-37. PubMed ID: 30409317
[TBL] [Abstract][Full Text] [Related]
16. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
[TBL] [Abstract][Full Text] [Related]
17. Definitive intensity-modulated radiotherapy concurrent with systemic therapy for oropharyngeal squamous cell carcinoma: Outcomes from an integrated regional Australian cancer centre.
Masoud Rahbari R; Winkley L; Hill J; Tahir AR; McKay M; Last A; Shakespeare TP; Dwyer P
J Med Imaging Radiat Oncol; 2016 Jun; 60(3):414-9. PubMed ID: 26786975
[TBL] [Abstract][Full Text] [Related]
18. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Molecular Assays for HPV Testing in Oropharyngeal Squamous Cell Carcinomas: A Population-Based Study in Northern Ireland.
Craig SG; Anderson LA; Moran M; Graham L; Currie K; Rooney K; Robinson M; Bingham V; Cuschieri KS; McQuaid S; Schache AG; Jones TM; McCance D; Salto-Tellez M; McDade SS; James JA
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):31-38. PubMed ID: 31666283
[TBL] [Abstract][Full Text] [Related]
20. Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains.
Klein S; Quaas A; Quantius J; Löser H; Meinel J; Peifer M; Wagner S; Gattenlöhner S; Wittekindt C; von Knebel Doeberitz M; Prigge ES; Langer C; Noh KW; Maltseva M; Reinhardt HC; Büttner R; Klussmann JP; Wuerdemann N
Clin Cancer Res; 2021 Feb; 27(4):1131-1138. PubMed ID: 33262137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
